- ►prsjournal.com S Bopp - British Journal of Ophthalmology, 2007 - bjo.bmj.com In the era of anti-vascular endothelial growth factor (VEGF) therapy for
exudative age-related macular degeneration (ARMD), a paradigm shift has emerged.
Until then, photodynamic therapy (PDT) was considered a successful ... Cited by 3 - Related articles - BL Direct - All 5 versions
VK Gullapalli, IK Sugino, MA Zarbin - Experimental Eye Research, 2007 - Elsevier The purpose of this study was to examine the change in integrin expression in
adult human retinal pigment epithelium (RPE) after culturing and to characterize
the role of integrins in RPE adhesion to aged submacular human Bruch's ... Cited by 2 - Related articles - All 3 versions
YM Buys - Canadian journal of ophthalmology. Journal canadien …, 2007 - ncbi.nlm.nih.gov 1: Can J Ophthalmol. 2007 Dec;42(6):789. Comment on: Can J Ophthalmol. 2007
Dec;42(6):807-11. Bevacizumab: the need for controlled studies to move forward. ... Cited by 2 - Related articles - BL Direct - All 3 versions
C FRENNESSON - ltarkiv.lakartidningen.se Åldersrelaterad makuladegeneration (AMD), och särskilt dess neovaskulära
form, är den vanligaste orsaken till all- varlig synnedsättning med förlust
av centralsynen och läsförmågan hos äldre personer. Tidigare behandling ... Related articles - View as HTML - All 2 versions
K Sun, H Cai, TH Tezel, D Paik, ER Gaillard, …, 2007 - molvis.org Methods: Explants of human Bruch's membrane were prepared from cadaver donor
eyes (aged 9–81years) within 48 h of death, and 6 mm punches were embedded
with the basal lamina in a 96-well plate. Approximately 50,000 ARPE-19 ... Cited by 3 - Related articles - Cached - All 4 versions
H Wang, C Cao, B Li, S Chen, J Yin, J Shi, D … - Cancer Immunology, Immunotherapy, 2008 - Springer Page 1. Cancer Immunol Immunother (2008) 57:677–684 DOI 10.1007/s00262-
007-0406-0 123 ORIGINAL ARTICLE Immunogenicity of Iodine ... Cited by 3 - Related articles - BL Direct - All 2 versions
AAOFO AAO - clienti.tio.ch Jeffrey Heier (Department of Ophthalmology, Harvard Medical School, Boston, MA,
USA) presented updated findings from the ANCHOR (Anti-VEGF Antibody for the
Treatment of Predominantly Classic Choroidal Neo- vascularisation in ... Related articles - View as HTML
CD Regillo, DM Brown, P Abraham, H Yue, T … - American Journal of Ophthalmology, 2008 - 80.35.244.216 RANIBIZUMAB (LUCENTIS; GENENTECH, INC, SOUTH San Francisco, California, USA) is
an intravitreally administered recombinant, humanized, monoclo- nal antibody
antigen-binding fragment (Fab) that neutral- izes all known active forms of ... Cited by 88 - Related articles - View as HTML - All 7 versions
RP Singh - members.medscape.com Jason Slakter [1] presented 1-year optical coherence tomographic (OCT) and
fluorescein angiographic results from the CLEAR-IT 2 trial -- a double-masked,
multicenter, phase 2 trial that is examining the use of intravitreal VEGF ... Cited by 1 - Related articles - All 2 versions
SVR Sadda - jhasio.com One of the most important questions with vas- cular endothelial growth factor
(VEGF) inhibitors for age-related macular degeneration is the rec- ommended
frequency of monitoring and whether the results of monitoring will guide ... Related articles
